Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 17 articles: HTML format

Single Articles

December 2021
1. KOLINGER GD, Vallez Garcia D, Kramer GM, Frings V, et al
   Effects of tracer uptake time in non-small cell lung cancer (18)F-FDG PET radiomics.
   J Nucl Med. 2021 Dec 21. pii: jnumed.121.262660. doi: 10.2967/jnumed.121.262660.
   PubMed     Abstract available
   
   
   August 2021
2. SMIT J, Borm FJ, Niemeijer AN, Huisman MC, et al
   PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
   J Nucl Med. 2021 Aug 12. pii: jnumed.121.262473. doi: 10.2967/jnumed.121.262473.
   PubMed     Abstract available
   
   
   July 2021
3. ZHOU X, Jiang J, Yang X, Liu T, et al
   First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET.
   J Nucl Med. 2021 Jul 29. pii: jnumed.121.262045. doi: 10.2967/jnumed.121.262045.
   PubMed     Abstract available
   
   
   
4. ROHRICH M, Leitz D, Glatting FM, Wefers AK, et al
   Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
   J Nucl Med. 2021 Jul 16. pii: jnumed.121.261925. doi: 10.2967/jnumed.121.261925.
   PubMed     Abstract available
   
   
   
5. NIEMEIJER AN, Oprea Lager DE, Huisman MC, Hoekstra OS, et al
   First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
   J Nucl Med. 2021 Jul 16. pii: jnumed.121.261926. doi: 10.2967/jnumed.121.261926.
   PubMed     Abstract available
   
   
   May 2021
6. GUBERINA M, Poettgen C, Metzenmacher M, Wiesweg M, et al
   PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.
   J Nucl Med. 2021 May 20. pii: jnumed.120.260646. doi: 10.2967/jnumed.120.260646.
   PubMed     Abstract available
   
   
   January 2021
7. LAFFON E, Marthan R
   Distribution Volume of (18)F-BMS-986192 in NSCLC Patients.
   J Nucl Med. 2021;62:144.
   PubMed    
   
   
   December 2020
8. STUSCHKE M, Pottgen C
   (18)F-FDG PET/CT for Target Volume Contouring in Lung Cancer Radiotherapy.
   J Nucl Med. 2020;61.
   PubMed    
   
   
   November 2020
9. AYATI N, Lee ST, Zakavi SR, Cheng M, et al
   Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.
   J Nucl Med. 2020 Nov 27. pii: jnumed.120.254508. doi: 10.2967/jnumed.120.254508.
   PubMed     Abstract available
   
   
   October 2020
10. CHRISTENSEN TN, Langer SW, Persson GF, Larsen KR, et al
    (18)F-FLT-PET/CT adds value to (18)F-FDG-PET/CT for diagnosing relapse after definitive radiotherapy in patients with lung cancer. Results of a prospective clinical trial.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.247742. doi: 10.2967/jnumed.120.247742.
    PubMed     Abstract available
    
    
    September 2020
11. GALLDIKS N, Abdulla DS, Scheffler M, Wolpert F, et al
    Treatment Monitoring of Immunotherapy and Targeted Therapy using (18)F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences.
    J Nucl Med. 2020 Sep 4. pii: jnumed.120.248278. doi: 10.2967/jnumed.120.248278.
    PubMed     Abstract available
    
    
    
12. CASTELLO A, Lopci E
    Reply: Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using (18)F-FDG PET/CT.
    J Nucl Med. 2020;61:1405.
    PubMed    
    
    
    June 2020
13. GIESEL F, Adeberg S, Syed M, Lindner T, et al
    FAPI-74 PET/CT Using Either (18)F-AlF or Cold-kit (68)Ga-labeling: Biodistribution, Radiation Dosimetry and Tumor Delineation in Lung Cancer Patients.
    J Nucl Med. 2020 Jun 26. pii: jnumed.120.245084. doi: 10.2967/jnumed.120.245084.
    PubMed     Abstract available
    
    
    
14. FERDINANDUS J, Barbato F, Chodyla M, Fendler WP, et al
    Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.
    J Nucl Med. 2020 Jun 12. pii: jnumed.120.245803. doi: 10.2967/jnumed.120.245803.
    PubMed     Abstract available
    
    
    April 2020
15. REYNOLDS JC, Maass-Moreno R, Thomas A, Ling A, et al
    FDG-PET assessment of malignant pleural mesothelioma: Total Lesion volume and Total Lesion Glycolysis; the central role of volume.
    J Nucl Med. 2020 Apr 13. pii: jnumed.119.238733. doi: 10.2967/jnumed.119.238733.
    PubMed     Abstract available
    
    
    February 2020
16. SEBAN RD, Schwartz LH, Bonardel G, Dercle L, et al
    Diagnosis of Hyper-progressive Disease in Patients Treated with Checkpoint Inhibitors using (18)F-FDG PET/CT.
    J Nucl Med. 2020 Feb 21. pii: jnumed.120.242768. doi: 10.2967/jnumed.120.242768.
    PubMed    
    
    
    June 2019
17. JREIGE M, Dunet V, Letovanec I, Prior JO, et al
    Pulmonary lymphangitic carcinomatosis: diagnostic performance of HRCT and (18)F-FDG-PET/CT in correlation to clinical pathologic outcome.
    J Nucl Med. 2019 Jun 21. pii: jnumed.119.229575. doi: 10.2967/jnumed.119.229575.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: